Organigram Global, Inc. Q2 FY2025 earnings call

• Rebranding to Organigram Global reflects the company's evolution into a diversified international cannabis leader. • In Canada, the cannabis market grew 4% y-o-y, with Organigram leading in vapes (21.7% share) and strong positions in pre-rolls and flower. • International sales saw a 177% y-o-y increase to $6.1M, with plans to expand in Australia and the US, and leveraging EU-GMP certification. • Motif integration is progressing, with synergies expected, production capacity expanded at Aylmer, and plans to double distillate and hydrocarbon isolate production. • The Collective Project acquisition has led to US beverage sales growth, with awards won and plans to launch beverages using FAST nanoemulsion technology. • Seed-based production accounted for 22% of harvest in Q2, with focus on genetic research. • Key focus areas for the coming quarter: accelerating international revenue growth, gaining Canada market share, increasing gross margins, and advocating for cannabis regulations.

In Q2 fiscal 2025, Organigram Global reported record-breaking revenue. Gross sales surged 79% to surpass $100 million for the first time in a quarter, and net revenue climbed 74% year-over-year to $65.6 million. International sales reached $6.1 million, a 177% increase from the prior year. In the Canadian market, the company is dominant in categories like vapes (21.7% share), pre-rolls, and flower, holding significant market shares. The Motif acquisition integration has impacted production, with commercial THC extraction moved to the Aylmer facility and production capacity expanded. Internationally, sales are growing due to relationships with customers abroad, and the Collective Project acquisition is contributing to US and Canadian beverage segments.

• Adjusted gross margin is expected to stabilize around 35% for fiscal 2025, with stronger performance anticipated in Q3/Q4 and a target of 40% gross margin in the second half of fiscal 2026. • Motif synergies are now expected to reach approximately $15 million next year, up from the previously disclosed $10 million. • The company is confident in being cash flow positive for the full year, with Q3/Q4 expected to be the strongest period for cash flow. • Plans to invest $8 million to $10 million in sustaining capital expenditures during fiscal 2025.

No specific detailed risks discussed in the transcript, but general risks associated with the cannabis industry such as market competition, regulatory changes, and supply chain issues could impact performance.

Q: Could you dive deeper into international growth outlook and balancing domestic and international capacity?

A: Beena Goldenberg mentioned balancing demands between domestic and international sales. International margins are higher, but domestic margins are improving. Expect more international sales in the back half, with a balancing act between the two.

Q: What's the potential for EBITDA margins in the medium-term?

A: Greg Guyatt stated synergies realized around $1.5 million of the $5 million target this year, with margin growth and cost management as key levers, targeting 40% gross margin in the second half of fiscal 2026.

Q: What drove sequential international sales growth?

A: Beena Goldenberg said it was meeting incremental demand from existing customers, not new ones, and EU-GMP certification will speed up fulfillment.

Q: Strategy for the US hemp-derived THC market?

A: Beena Goldenberg said focusing on trial and awareness, leveraging strong products and sampling, investing to drive growth, with distribution expansion planned.